The Congestive Study

The Congestive Study is exploring a new potential treatment for Respiratory Syncytial Virus (RSV).

RSV is the most significant cause of lower respiratory tract infections across all age groups, but it is particularly common among older adults. In Australia, almost all children experience at least one RSV infection within the first two years of life. Globally, approximately 336,000 older adults are hospitalized each year due to RSV-associated acute respiratory infections. In Australia, the impact is also significant, with many older adults requiring hospitalization during the RSV season. There is an urgent need for an RSV vaccine across all population groups, as currently, no approved RSV vaccine is available. This study aims to address this critical gap in healthcare.

The study drug is administered via a single intramuscular injection into the upper arm muscle. This method ensures that participants receive the treatment efficiently and effectively.

The trial has been approved by an independent ethics committee, and eligible participants will be reimbursed for their time.

Call us at 1800 243 733 to discuss your eligibility today!